Niagen Bioscience named Evotec as contract research organization for NB4168, a move aimed at accelerating development of the drug candidate. NB4168 has already

Niagen Bioscience named Evotec as contract research organization for NB4168, a move aimed at accelerating development of the drug candidate. NB4168 has already received FDA Rare Pediatric Disease and EMA Orphan designations for ataxia-telangiectasia.